Omnicell Inc (OMCL) News

Omnicell Announces First Quarter 2024 Results

Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,”...

Omnicell Announces XT Amplify

Multi-year Innovation Program Designed to Maximize Value and Outcomes for XT Automated Dispensing System...

Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the first quarter...

Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will present at the virtual KeyBanc Annual Life Sciences...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results

Full Year 2023 GAAP Revenues of $1.147 billion Full Year 2023 GAAP net loss of $20 million and GAAP net loss per diluted share of $0.45 Full Year...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies...

Form 8-K - Current report